HEALTH AND DISEASE STATUS IN THE BLSA--THE PROSTATE GLAND

去年完成了两项研究。 第一个检查了 前列腺特异性抗原作为前列腺癌的标志物。 纵向 分析表明，经年龄调整后的患病率存在显着差异 前列腺癌、BPH受试者和对照者之间PSA的变化。 在 PSA在BPH和前列腺癌受试者之间没有差异的时间（5 诊断前10年），PSA的变化率显著高于 前列腺癌患者。 研究结果表明，PSA的变化 可能是一个敏感和特异的早期标记， 前列腺癌 第二项研究估计了BLSA参与者的PSA生长曲线， 没有前列腺疾病、BPH病例和前列腺癌病例的证据。 对照组参与者的PSA变化最小，因此表明， 前列腺增生不是正常前列腺生长的自然结果，而是一种独立的疾病。 致病过程 前列腺增生病例呈逐渐和持续加速的趋势 随着年龄的增长，PSA 癌症病例表现出早期缓慢的线性 PSA增长阶段，然后是快速指数增长阶段。

In the past year two studies have been completed. The first has examined prostate specific antigen as a marker of prostatic cancer. Longitudinal analyses demonstrated a significant age adjusted difference in rate of change in PSA between subjects with prostate cancer, BPH and controls. At a time when PSA did not differ between BPH and prostate cancer subjects (5 years before diagnosis), rate of change in PSA was significantly greater in subjects with prostate cancer. The findings suggest that of change in PSA may be a sensitive and specific early marker for the development of prostate cancer. The second study estimated the PSA growth curves of BLSA participants with no evidence of prostate disease, BPH cases, and prostate cancer cases. Control participants exhibited minimal change in PSA thus suggesting that BPH is not a natural outcome of normal prostate growth, but is a separate pathogenic process. BPH cases showed a gradual and continuing acceleration in PSA with increasing age. Cancer cases exhibited an early slow linear phase of PSA growth followed by a rapid exponential growth phase.